You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
仟源醫藥(300254.SZ):子公司取得一種純化帕瑞昔布鈉的設備及方法的發明專利證書
格隆匯 06-02 17:39

格隆匯6月2日丨仟源醫藥(300254.SZ)公佈,公司子公司江蘇嘉逸醫藥有限公司於近日收到國家知識產權局頒發的“一種純化帕瑞昔布鈉的設備及方法”發明專利證書。

一種純化帕瑞昔布鈉的設備及方法,是提出一種純化藥用晶型帕瑞昔布鈉的設備組合及相應的純化方法。本發明在優化後的帕瑞昔布鈉結晶溶劑和結晶條件的基礎上,通過對新型設備的創新研製和現有設備的創新組合,將工藝和設備進行有機結合,在保證最終產品為藥用晶型的前提下,保證了生產過程的穩定可控。該種設備組合,可保證優化後的帕瑞昔布鈉結晶工藝全程温度穩定,可有效避免產品在壓濾過程中提前析出而造成的管路堵塞和產品損失;優化後的帕瑞昔布鈉結晶工藝的結晶速率穩定,對雜質的去除有較強的作用,可有效保證原料藥的精製效果。該設備組合除可適用於帕瑞昔布鈉的結晶工序以外,也適用於其他溶解性極佳,但又無更合適結晶溶劑的原料藥的結晶工序,具有較廣泛的應用空間。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account